Anita K Dunbier

Summary

Affiliation: Institute of Cancer Research
Country: UK

Publications

  1. pmc Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer
    Marion T Weigel
    Breakthrough Breast Cancer Centre, Institute of Cancer Research, 237 Fulham Road, London SW3 6JJ, UK
    Breast Cancer Res 14:R78. 2012
  2. pmc A novel diffuse gastric cancer susceptibility variant in E-cadherin (CDH1) intron 2: a case control study in an Italian population
    Soroush Nasri
    Cancer Genetics Laboratory, Department of Biochemistry, University of Otago, Dunedin 9054, Aotearoa New Zealand
    BMC Cancer 8:138. 2008
  3. doi Progress in aromatase research and identification of key future directions
    Anita K Dunbier
    Academic Department of Biochemistry, Royal Marsden Hospital, London SW3 6JJ, United Kingdom
    J Steroid Biochem Mol Biol 118:311-5. 2010
  4. pmc Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women
    Anita K Dunbier
    Academic Department of Biochemistry, Royal Marsden Hospital, Fulham Rd, London, SW3 6JJ, United Kingdom
    J Clin Oncol 28:1161-7. 2010
  5. doi New and translational perspectives of oestrogen deprivation in breast cancer
    Anita K Dunbier
    Royal Marsden Hospital, London, United Kingdom
    Mol Cell Endocrinol 340:137-41. 2011
  6. doi Association between breast cancer subtypes and response to neoadjuvant anastrozole
    Anita K Dunbier
    Royal Marsden Hospital, London, United Kingdom
    Steroids 76:736-40. 2011
  7. pmc ESR1 is co-expressed with closely adjacent uncharacterised genes spanning a breast cancer susceptibility locus at 6q25.1
    Anita K Dunbier
    Royal Marsden Hospital, London, United Kingdom
    PLoS Genet 7:e1001382. 2011
  8. doi Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance
    Anita K Dunbier
    Royal Marsden Hospital, London, United Kingdom
    Clin Cancer Res 19:2775-86. 2013
  9. doi Close and stable relationship between proliferation and a hypoxia metagene in aromatase inhibitor-treated ER-positive breast cancer
    Zara Ghazoui
    Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom
    Clin Cancer Res 17:3005-12. 2011
  10. doi Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy
    Mitch Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, and Breakthrough Breast Cancer Centre, Institute of Cancer Research, London, SW3 6JJ, United Kingdom
    J Clin Oncol 31:2783-90. 2013

Collaborators

Detail Information

Publications11

  1. pmc Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer
    Marion T Weigel
    Breakthrough Breast Cancer Centre, Institute of Cancer Research, 237 Fulham Road, London SW3 6JJ, UK
    Breast Cancer Res 14:R78. 2012
    ..Estrogen (E) mediates its effects by binding to the ER. Therapies targeting the estrogenic stimulation of tumor growth reduce mortality from ER+ breast cancer. However, resistance remains a major clinical problem...
  2. pmc A novel diffuse gastric cancer susceptibility variant in E-cadherin (CDH1) intron 2: a case control study in an Italian population
    Soroush Nasri
    Cancer Genetics Laboratory, Department of Biochemistry, University of Otago, Dunedin 9054, Aotearoa New Zealand
    BMC Cancer 8:138. 2008
    ..Recently, a new regulatory region essential for CDH1 transcription has been identified in CDH1 intron 2...
  3. doi Progress in aromatase research and identification of key future directions
    Anita K Dunbier
    Academic Department of Biochemistry, Royal Marsden Hospital, London SW3 6JJ, United Kingdom
    J Steroid Biochem Mol Biol 118:311-5. 2010
    ....
  4. pmc Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women
    Anita K Dunbier
    Academic Department of Biochemistry, Royal Marsden Hospital, Fulham Rd, London, SW3 6JJ, United Kingdom
    J Clin Oncol 28:1161-7. 2010
    ..The AvERG is a new experimental tool for the study of putative estrogenic stimuli of breast cancer...
  5. doi New and translational perspectives of oestrogen deprivation in breast cancer
    Anita K Dunbier
    Royal Marsden Hospital, London, United Kingdom
    Mol Cell Endocrinol 340:137-41. 2011
    ..Testing new agents and combinations in short-term pre-surgical studies using biomarkers such as Ki67 is critical for increasing the rate at which new rational combinations can be assessed for efficacy...
  6. doi Association between breast cancer subtypes and response to neoadjuvant anastrozole
    Anita K Dunbier
    Royal Marsden Hospital, London, United Kingdom
    Steroids 76:736-40. 2011
    ..These results suggest that in the short-term, Luminal A and B tumours may gain similar benefit from an AI but that the higher residual Ki67 level seen in Luminal B is indicative of poorer long term outcome...
  7. pmc ESR1 is co-expressed with closely adjacent uncharacterised genes spanning a breast cancer susceptibility locus at 6q25.1
    Anita K Dunbier
    Royal Marsden Hospital, London, United Kingdom
    PLoS Genet 7:e1001382. 2011
    ..The co-expression and function of these genes may be important influences on the recently identified relationship between SNPs in this region and breast cancer risk...
  8. doi Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance
    Anita K Dunbier
    Royal Marsden Hospital, London, United Kingdom
    Clin Cancer Res 19:2775-86. 2013
    ..We aimed to identify in clinical breast cancer those genes and pathways most associated with resistance to aromatase inhibitors by examining the global transcriptional effects of AI treatment...
  9. doi Close and stable relationship between proliferation and a hypoxia metagene in aromatase inhibitor-treated ER-positive breast cancer
    Zara Ghazoui
    Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom
    Clin Cancer Res 17:3005-12. 2011
    ..Proliferation was measured by Ki67 and a proliferation metagene derived from two published breast cancer data sets...
  10. doi Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy
    Mitch Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, and Breakthrough Breast Cancer Centre, Institute of Cancer Research, London, SW3 6JJ, United Kingdom
    J Clin Oncol 31:2783-90. 2013
    ..It is frequently estimated using the Oncotype DX recurrence score (RS). The PAM50 risk of recurrence (ROR) score provides an alternative approach, which also identifies intrinsic subtypes...
  11. doi Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer
    Mitch Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, London, United Kingdom
    Clin Cancer Res 14:8019-26. 2008
    ..Rigorous comparison of these emerging markers with current treatment selection criteria will be required to determine whether they offer significant benefit to justify their use...